Latest close: a new 52-week highSep 8, 2026what changed →
Is the price fair?
What TXG's price assumes
10x Genomics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 4.26× revenue.
4.26
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.7%
Free cash flow yield · Health Information Services median 5.7%
- Growth the price implies
- +14%
Growth the price implies · The price pays for +14% free cash flow growth a year for a decade; revenue has grown +6.0% a year over the last three.
- Price / book
- 3.34
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 3.34
- EV / EBIToperating margin −6.1%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $122M
- Market capitalisation
- $4.54B
- 3-year revenue growth
- +6.0%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #1 of 13 by Smart Score